-
公开(公告)号：KR1020090093733A
公开(公告)日：2009-09-02
申请号：KR1020080043926
申请日：2008-05-13
Applicant: 조선대학교산학협력단
Abstract: A novel microorganism which produces a chemical having excellent antibacterial activity on methicillin-resistant Saphylococcus aureus (MRSA) is provided to enhance the efficiency of animal feed with high antibacterial activity and use as a feed additive. A Nocardia sp. CS682 (KCTC 11297BP) is isolated from soil. The Nocardia sp. CS682 (KCTC 11297BP) has 16s rRNA (ibosomal RNA) of the sequence number 1. The Nocardia sp. CS682 or fermentation culture liquid containing the nargenicin produced from the strain is used as an animal feed additive or promoting agent of animal growth.
Abstract translation: 提供了一种能产生对耐甲氧西林金黄色葡萄球菌（MRSA）具有优异抗菌活性的化学物质的新型微生物，以提高具有高抗菌活性的动物饲料的效率，并用作饲料添加剂。 诺卡氏菌 CS682（KCTC 11297BP）从土壤中分离。 诺卡氏菌 CS682（KCTC 11297BP）具有序列1的16s rRNA（异型RNA）。诺卡氏菌属 CS682或含有由该菌株产生的Nargenicin的发酵培养液用作动物饲料添加剂或动物生长促进剂。
-
Patent Agency Ranking
公开(公告)号：KR1020110049967A
公开(公告)日：2011-05-13
申请号：KR1020090106758
申请日：2009-11-06
Applicant: 조선대학교산학협력단
IPC: A61K36/258 , A61P35/02 , A61K31/203 , A61K31/59
CPC classification number: A61K36/258 , A61K2236/33 , Y10S514/908
Abstract: PURPOSE: An anticancer drug composition containing ginseng extract is provided to differenetiate undifferentiated promyelocytic blood cells and to be used as a therapeutic agent for promyelocytic leukemia. CONSTITUTION: An anticancer composition contains methanol extract of ginseng, 1,25-dihydroxy vitamin D_3(1,25-(OH)_2D_3) or all-transfretinoic acid mixture and carrier. A therapeutic agent for promyeolocytic leukemia contains the ginseng methanol extract as an active ingredient and pharmaceutically acceptable carrier. The final concentration of 1,25-(OH)_2D_3, retinoic acid, and nargenicin is 5 nM, 50 nM, and 200 mM, respectively.
Abstract translation: 目的：提供含有人参提取物的抗癌药物组合物，以分化未分化的前髓细胞血细胞，并用作早幼粒细胞白血病的治疗剂。 构成：抗癌组合物含有人参甲醇提取物，1,25-二羟基维生素D_3（1,25-（OH）_2D_3）或全转氨酸的混合物和载体。 前列腺细胞性白血病的治疗剂含有人参甲醇提取物作为活性成分和药学上可接受的载体。 1,25-（OH）_2D_3，视黄酸和Nargenicin的最终浓度分别为5nM，50nM和200mM。
-
公开(公告)号：KR1020130054518A
公开(公告)日：2013-05-27
申请号：KR1020110119926
申请日：2011-11-17
Applicant: 조선대학교산학협력단 , 광주대학교산학협력단
CPC classification number: A23L17/60 , A23L3/44 , A23V2002/00 , A23V2250/202 , A23V2300/14 , A61K36/04
Abstract: PURPOSE: A usage for health promoting food, a whitening cosmetic product, and a medicine using a seaweed methanol extract are provided to offer various biological activities including an antioxidant effect, a whitening effect, and an anti-inflammatory effect. CONSTITUTION: Porphyra yezoensis, Undaria pinnatifida, Hizikia fusiformis, Capsosiphon fulvescens, Enteromorpha Linza are collected. The seaweeds are washed and dried, then soaked in 500ml of 70% methanol for 100g of seaweeds before extracting for a week. The extract is filtered by using filtering paper. The filtered material is freeze-dried after the concentration by using an evaporator. [Reference numerals] (AA) Hizikia fusiformis; (BB) Porphyra yezoensis; (CC) Undaria pinnatifida; (DD) Enteromorpha Linza; (EE) Capsosiphon fulvescens
Abstract translation: 目的：提供健康促进食品，美白化妆品和使用海草甲醇提取物的药物的用途，以提供各种生物活性，包括抗氧化作用，美白效果和抗炎作用。 构成：收集紫菜，紫花苜蓿，烟丝，辣椒，枸杞子。 将海藻洗涤并干燥，然后在500ml 70％甲醇中浸泡100g海藻，然后提取一周。 萃取液用滤纸过滤。 通过使用蒸发器将过滤的物质在浓缩后冷冻干燥。 （AA）Hizikia fusiformis; （BB）紫菜紫菜; （CC）Undaria pinnatifida; （DD）Enteromorpha Linza; （EE）Capsosiphon fulvescens
-
公开(公告)号：KR101040468B1
公开(公告)日：2011-06-09
申请号：KR1020080043926
申请日：2008-05-13
Applicant: 조선대학교산학협력단
Abstract: 본 발명은 메티실린 내성 포도상구균 균주에 탁월한 항균 활성을 나타내는 화학물질을 생산하는 새로운 미생물 균주 및 이 균주에서 생산되는 항균 활성 물질을 함유하고 있는 배양액에 관한 것이다. 본 발명의 신규 미생물 및 이로부터 생산되는 항균활성 물질을 포함하는 배양액은 기존 항생제의 계속되는 사용으로 인한 메티실린 내성 균주의 내성화 문제의 해결에 활용될 수 있다. 특히 본 배양액은 동물사료용 항생제를 대체 할 수 있으며 동물성장을 촉진하고 사료효율을 개선시키는 사료첨가제 성분으로 효과적으로 사용될 수 있다.
나르제니신, 사료첨가제-
公开(公告)号：KR100807196B1
公开(公告)日：2008-02-28
申请号：KR1020060128398
申请日：2006-12-15
Applicant: 조선대학교산학협력단
IPC: A61K35/618 , A61K9/00
CPC classification number: A61K35/618 , A61K9/0053
Abstract: An extract of Scapharca broughtonii is provided to be able to inhibit the induction of promyelocytic leukemia and auto-immune diseases, thereby being widely utilized as an anti-cancer agent or for treating various immune-diseases. A pharmaceutical composition for treating promyelocytic leukemia comprises an alcohol extract of Scapharca broughtonii and a pharmaceutically acceptable carrier. A method for preparing an alcohol fraction of the Scapharca broughtonii comprises the steps of: (a) after removing muscle from the Scapharca broughtonii and washing it with ice-cooled salt, freeze-drying it; (b) after finely cutting the frozen muscle and dipping it in a mixture solvent of ethanol and water in a volumetric ratio of 60:40 at room temperature of 3-10 days, evaporating an ethanol-aqueous solution obtained by removing remaining solid phase materials therefrom through centrifugation under reduced pressure to eliminate the ethanol; (c) adding activated carbon to the aqueous solution and agitating it; (d) separating the activated carbon from the aqueous solution through filtration and washing it with distilled water; (e) respectively eluting effective ingredients from the activated carbon using an 80% aqueous solution of acetone and 100% ethanol; (f) putting two eluents together and drying it under reduced pressure; (g) subjecting the dried material to a stepwise elution using 100% ethyl acetate, 100% ethanol and 100% methanol to fractionate; and (h) respectively concentrating the obtained ethanol fraction and methanol fraction and respectively purifying them through a silica-gel chromatography.
Abstract translation: 提供石斛提取物以能够抑制早幼粒细胞白血病和自身免疫疾病的诱导，从而被广泛用作抗癌剂或用于治疗各种免疫疾病。 一种用于治疗早幼粒细胞白血病的药物组合物，其包含石菖蒲的酒精提取物和药学上可接受的载体。 用于制备石菖蒲酒精馏分的方法包括以下步骤：（a）从玻璃after after中除去肌肉后，用冰冷却的盐洗涤，冷冻干燥; （b）精细切割冷冻肌肉后，在3-10天的室温下将体积比为60:40的乙醇和水的混合溶剂浸渍，蒸发除去剩余的固相物质得到的乙醇 - 水溶液 通过在减压下离心以除去乙醇; （c）向水溶液中加入活性炭并搅拌; （d）通过过滤从水溶液中分离活性炭并用蒸馏水洗涤; （e）使用80％丙酮和100％乙醇水溶液分别从活性炭洗脱有效成分; （f）将两种洗脱液放在一起，减压干燥; （g）使用100％乙酸乙酯，100％乙醇和100％甲醇对干燥的物质进行逐步洗脱以分馏; 和（h）分别浓缩得到的乙醇级分和甲醇级分，并通过硅胶色谱法分别纯化。
-
公开(公告)号：KR1020070099899A
公开(公告)日：2007-10-10
申请号：KR1020060031251
申请日：2006-04-06
Applicant: 조선대학교산학협력단
CPC classification number: A61K31/35 , A61K47/18 , A61K47/6901 , A61K2121/00
Abstract: A polyether antibiotics-carrier protein conjugate is provided to be used as an antigen for producing a monoclonal antibody specifically bound to the polyether antibiotics, thereby allowing the obtained monoclonal antibody to be used for rapidly and precisely detecting a very small amount of the polyether antibiotics contained in a mixture such as an animal feed. A method for preparing a polyether antibiotics-carrier protein conjugate comprises a step of: reacting a compound obtained by reacting a polyether antibiotics having a carboxyl group with a compound having a carbodiimide group with a carrier protein having an amine nucleophilic group; or reacting a polyether antibiotics having a carboxyl group with a mixture anhydride in the presence of a solvent and then reacting it with a carrier protein having an amine nucleophilic group, wherein the polyether antibiotics are selected from the group consisting of monensin, salinomycin, laidlomycin, narasin, lasalocid and maduramicin and the carrier protein is selected from the group consisting of bovine serum albumin(BSA, ovalbumin and keyhole limpet hemocyanin( KLH)).
Abstract translation: 提供聚醚抗生素 - 载体蛋白结合物作为用于制备与聚醚抗生素特异性结合的单克隆抗体的抗原，从而使得到的单克隆抗体用于快速且精确地检测非常少量的包含的聚醚抗生素 在混合物如动物饲料中。 制备聚醚抗生素 - 载体蛋白结合物的方法包括以下步骤：使具有羧基的聚醚抗生素与具有碳二亚胺基团的化合物反应得到的化合物与具有胺亲核基团的载体蛋白质反应; 或在溶剂存在下使具有羧基的聚醚类抗生素与混合酸酐反应，然后使其与具有胺亲核基团的载体蛋白反应，其中所述聚醚抗生素选自莫能菌素，盐霉素，舍洛霉素， 纳沙星，拉沙里菌素和马杜米霉素，载体蛋白选自牛血清白蛋白（BSA，卵清蛋白和匙孔血蓝蛋白（KLH））。
-
-
-
-
-
Search Results
6
records
(took 0.031 seconds)
